Kissei Pharmaceutical Co., Ltd.

Quick facts

Marketed products

• KAD-1229 · Cardiovascular
  KAD-1229 is a potassium channel opener that relaxes vascular smooth muscle to reduce blood pressure.
• KLH-2109 · Cardiovascular
  KLH-2109 is a potassium channel opener that relaxes vascular smooth muscle to reduce blood pressure.

Phase 3 pipeline

• JR-131 · Oncology
  JR-131 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to treat FGFR-driven cancers.
• KPS-0373 · Diabetes
  KPS-0373 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.
• KPS-0373, High dose · Pain Management
  KPS-0373 is a selective TRPV1 antagonist that blocks pain signaling through the transient receptor potential vanilloid 1 channel.
• KPS-0373, Low dose · Diabetes
  KPS-0373 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.
• MR13A9 · Diabetes
  MR13A9 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.
• PA21 · Diabetes
  PA21 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.

Phase 2 pipeline

• KCT-0809 · Diabetes
  KCT-0809 is a small molecule that targets the SGLT2 receptor.
• KDT-3594
• KLS-0611
• KSO-0400
• KSP-0243
• KUX-1151
• KWA-0711

Phase 1 pipeline

• [14C]KWA-0711
• YS110

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kissei Pharmaceutical Co., Ltd. portfolio CI brief
• Kissei Pharmaceutical Co., Ltd. pipeline updates RSS